ArticleFrontiers in medicine2025
Case Report: Primary pulmonary lymphoma with CT negative and PET high metabolism combined with hemophagocytic syndrome.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary pulmonary diffuse large B-cell lymphoma (DLBCL) is usually accompanied by imaging visible lesions. Cases with normal CT morphology and high PET metabolism are extremely rare, especially when combined with hemophagocytic syndrome (HLH). Case: We present the case of a 50-year-old man who presented with fever of unknown origin (FUO) in March 2023. Chest CT showed no abnormalities, while positron emission tomography/computed tomography (PET/CT) showed diffuse hypermetabolism in both lungs (SUVmax 5.1) and slightly increased bone marrow uptake (SUVmax 3.1). Laboratory tests showed a significant increase in ferritin (1132.37 ng / mL) and C-reactive protein (CRP) (115.38 mg/L). Bone marrow smears showed hemophagocytosis. A lung biopsy guided by PET metabolic focus confirmed DLBCL (germinal center type). Complete metabolic remission was achieved after four cycles of R-CEOP chemotherapy. Conclusion: Primary pulmonary lymphoma (PPL) should be considered in patients with diffuse increased 18F-FDG uptake in both lungs and accompanied by hemophagocytic syndrome when they do not meet the imaging findings of common lung diseases, and the site of increased uptake should be selected for pathological biopsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.